Significant Strategic Collaborations (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 287,603	$ 112,927	$ 478,819	$ 169,676
Research and development expenses	524,550	307,900	1,154,279	667,551
Prepaid expenses and other current asset	917,826		917,826		$ 841,958
Takeda [Member] \| Royalty Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	300,000	100,000	500,000	$ 200,000
Serum Institute [Member] \| Royalty Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	0
Syn Bio [Member] \| Royalty Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	0
Pharmsynthez [Member] \| Royalty Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	$ 0
Scripps Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses			1,500,000
Prepaid expenses and other current asset	$ 200,000		$ 200,000		$ 200,000